Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its ...
The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the ...
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...
(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its ...
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback